

USSN: 10/804,380

Ref. No. PC 26615


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

We claim:

1. (Currently Amended): A compound of formula I



I

or a pharmaceutically acceptable salt thereof wherein

Y is

- a) $-\text{NHC}(=\text{W})\text{R}^1$,
- b) $-\text{O-het}$, $-\text{S-het}$, or $-\text{NH-het}$;

X is

- a) $-\text{O}-$,
- b) $-\text{S}(=\text{O})_i-$, or
- c) $-\text{S}(=\text{O})(=\text{NR}^4)-$;

W is

- a) O, or
- b) S;

R^1 is

- a) H,
- b) C_{1-8} alkyl,
- c) C_{3-6} cycloalkyl,
- d) OC_{1-4} alkyl,
- e) SC_{1-4} alkyl,
- f) NH_2 ,
- g) NHC_{1-6} alkyl, or

USSN: 10/804,380

Ref. No. PC 26615

h) $N(C_{1-6} \text{ alkyl})_2$; R^2 is

- a) H,
- b) halo, or
- c) C_{1-4} alkyl;

 R^3 is

- a) ~~H,~~
- b) ~~C_{1-8} alkyl,~~
- c) ~~aryl,~~
- d) ~~het,~~
- e) ~~$C(-W)R^5$,~~
- ~~f) $C(-O)OR^6$, or~~
- g) ~~$S(-O)_iR^7$;~~

 R^4 is

- a) H, or
- b) C_{1-8} alkyl;

 R^5 is

- a) ~~H,~~
- b) ~~aryl,~~
- c) ~~het,~~
- d) ~~NR^8R^9 , or~~
- e) ~~C_{1-8} alkyl;~~

 R^6 is

- a) ~~C_{1-8} alkyl,~~
- b) ~~aryl, or~~
- c) ~~het,~~

 R^7 is

- a) aryl,
- b) het,
- c) NR^8R^9 , or
- d) C_{1-8} alkyl;

USSN: 10/804,380

Ref. No. PC 26615

R^8 and R^9 are independently

- a) H,
- b) C_{1-6} alkyl, or
- c) aryl;

wherein $>G-E-$ is $>N-C-$ and Q is a carbon atom, or $>G-E$ is $>C=C-$ and Q is a nitrogen atom;

aryl is a phenyl radical or an ortho-fused bicyclic carbocyclic radical wherein at least one ring is aromatic;

het is a C-linked five- (5) or six- (6) membered saturated or unsaturated heterocyclic ring having 1, 2, or 3 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, which is optionally fused to a benzene ring;

at each occurrence, alkyl or cycloalkyl is optionally substituted with one or more OR^8 , halo, aryl, $S(=O)_iR^7$, $C(=W)R^8$, $OC(=O)C_{1-6}$ alkyl, or NR^8R^9 ;

at each occurrence, aryl is optionally substituted with one or more halo, OH, CF_3 , OC_{1-6} alkyl, CN, C_{1-6} alkyl, $S(=O)_iR^7$, $C(=W)R^8$, $OC(=O)R^8$, $NHC(=O)R^8$, or NR^8R^9 ;


at each occurrence, het is optionally substituted with one or more halo, OH, CF_3 , OC_{1-6} alkyl, CN, C_{1-6} alkyl, $S(=O)_iR^7$, $C(=W)R^8$, $OC(=O)R^8$, $NHC(=O)R^8$, or NR^8R^9 , oxo, or oxime;

m is 0, 1, 2, 3, or 4;

n is 0, 1, 2, 3, or 4; with the proviso that m and n taken together are 3 or 4; ~~if m is 2 n is not 2, and if n is 2 m is not 2~~; and

j is 0, 1, or 2.

2. (original): A compound of claim 1 which is a compound of formula IA:



IA.

3. (original): A compound of claim 2 wherein R^2 is H.

USSN: 10/804,380

Ref. No. PC 26615

4. (original): A compound of claim 2 wherein R^1 is C_{1-6} alkyl.

5. (original): A compound of claim 2 wherein R^1 is methyl.

Claims 6-13: Canceled


14. (Currently Amended): A compound of claim 4 or 6 wherein m is 1 and n is 3.

15. (Currently Amended): A compound of claim 4 or 6 wherein m is 0 and n is 4.

16. (Currently Amended): A compound of claim 4 or 6 wherein m is 1 and n is 2.

17. (Currently Amended): A compound of claim 4 or 6 wherein m is 2 and n is 1.


18. (original): A compound of claim 1 which is a compound of formula IB:



IB

wherein A is O, S or NH and het is isoxazol-3-yl, isoxazol-5-yl, 1,2,4-oxadiazol-3-yl, isothiazol-3-yl, 1,2,4-thiadiazol-3-yl or 1,2,5-thiadiazol-3-yl.

19. (original): A compound of claim 1 which is a compound of formula IC:




USSN: 10/804,380

Ref. No. PC 26615

IC.

20. (original): A compound of claim 1 which is a compound of formula ID



ID

wherein A is O, S or NH and het is isoxazol-3-yl, isoxazol-5-yl, 1,2,4-oxadiazol-3-yl, isothiazol-3-yl, 1,2,4-thiadiazol-3-yl or 1,2,5-thiadiazol-3-yl.

21. (original): A method for treating microbial infections comprising: administering to a mammal in need thereof an effective amount of a compound of claim 1.
22. (original): The method of claim 21 wherein said compound is administered orally, parenterally, transdermally, or topically.
23. (original): The method of claim 21 wherein said compound is administered in an amount of from about 0.1 to about 150 mg/kg of body weight/day.
24. (original): The method of claim 21 wherein said compound is administered in an amount of from about 3 to about 100 mg/kg of body weight/day.
25. (Currently Amended): The method of claim 21 wherein said infection is a skin infection.
26. (Currently Amended): The method of claim 21 wherein the infection is an eye infection.
27. (original): A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

USSN: 10/804,380

Ref. No. PC 26615

28. (original): The method of claim 21 wherein said compound is administered in an amount of 600mg per day by IV or by oral.
29. (Currently Amended): The method of claim 21 wherein said mammal is a human.
30. (new): The compound of claim wherein if m is 2 then n is not 2, and if n is 2 then m is not 2.
31. (New) A compound of claim 4 wherein X is S, SO, or SO₂.
32. (New) A compound of claim 4 wherein X is O.
33. (New) A compound of claim 31 wherein m is 2 and n is 2.
34. (New) A compound of claim 1 which is
- (-)-N-[[[(5S)-3-(3,4-dihydro-1H-2-benzopyran-6-yl)-2-oxo-5-oxazolidinyl]methyl]acetamide,
 - (+)-N-[[[(5S)-3-(3,4-dihydro-1H-2-benzopyran-6-yl)-2-oxo-5-oxazolidinyl]methyl]ethanethioamide,
 - (-)-N-[[[(5S)-3-(3,4-dihydro-1H-2-benzothiopyran-6-yl)-2-oxo-5-oxazolidinyl]methyl]acetamide,
 - (+)-N-[[[(5S)-3-(3,4-dihydro-1H-2-benzothiopyran-6-yl)-2-oxo-5-oxazolidinyl]methyl]ethanethioamide,
 - (+)-N-[[[(5S)-3-(3,4-dihydro-2,2-dioxido-1H-2-benzothiopyran-6-yl)-2-oxo-5-oxazolidinyl]methyl]ethanethioamide,
 - (+)-N-[[[(5S)-3-(3,4-dihydro-1H-2-benzopyran-7-yl)-2-oxo-5-oxazolidinyl]methyl]ethanethioamide,
 - (-)-N-[[[(5S)-3-(3,4-dihydro-1H-2-benzothiopyran-7-yl)-2-oxo-5-oxazolidinyl]methyl]acetamide,

USSN: 10/804,380

Ref. No. PC 26615

- h) (+)-N-[[[(5S)-3-(3,4-dihydro-1H-2-benzothiopyran-7-yl)-2-oxo-5-oxazolidinyl]methyl]ethanethioamide,
- i) (+)-N-[[[(5S)-3-(3,4-dihydro-2,2-dioxido-1H-2-benzothiopyran-7-yl)-2-oxo-5-oxazolidinyl]methyl]ethanethioamide,
- j) N-[[[(5S)-3-(3,4-dihydro-2-oxido-1H-2-benzothiopyran-7-yl)-2-oxo-5-oxazolidinyl]methyl]acetamide,
- k) N-[[[(5S)-2-oxo-3-(1,2,4,5-tetrahydro-3-benzothiepin-7-yl)-5-oxazolidinyl]methyl]acetamide,
- l) N-[[[(5S)-2-oxo-3-(1,2,4,5-tetrahydro-3,3-dioxido-3-benzothiepin-7-yl)-5-oxazolidinyl]methyl]acetamide,
- m) N-[[[(5S)-2-oxo-3-(1,2,4,5-tetrahydro-3-benzothiepin-7-yl)-5-oxazolidinyl]methyl]ethanethioamide, or
- n) N-[[[(5S)-2-oxo-3-(1,2,4,5-tetrahydro-3,3-dioxido-3-benzothiepin-7-yl)-5-oxazolidinyl]methyl]ethanethioamide.